Suchergebnisse - "Usmani, Saad Z"

PubPharm (308)

71

Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

enthalten in: Clinical lymphoma, myeloma & leukemia | 2022

von Weisel, K. | Krishnan, A. | Schecter, J. | +14

72

Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study

enthalten in: British journal of haematology | 2022

von Landgren, O. | Weisel, K. | Rosinol, L. | +9

73

Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma

enthalten in: Transplantation and cellular therapy | 2022

von Holstein, S. | Asimakopoulos, F. | Azab, A. | +20

74

Teclistamab in Relapsed or Refractory Multiple Myeloma

enthalten in: The New England journal of medicine | 2022

von Moreau, P. | Garfall, A. | van de Donk, N. | +31

CommentIn: N Engl J Med. 2022 Aug 11;387(6):558-561. - PMID 35947712

75

Proceedings from the blood and marrow transplant clinical trials network myeloma intergroup workshop on immune and cellular therapy in multiple myeloma

enthalten in: Transplantation and cellular therapy | 30 July 2022

von Holstein, S. | Asimakopoulos, F. | Azab, A. | +20

76

Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma : A multi-institutional experience

enthalten in: American journal of hematology | 2022

von Mohan, M. | Becnel, M. | Shah, U. | +29

77

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

enthalten in: Blood cancer discovery | 2022

von Davies, F. | Pawlyn, C. | Usmani, S. | +27

78

Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma

enthalten in: The oncologist | 2022

von Jakubowiak, A. | Kumar, S. | Medhekar, R. | +10

79

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

enthalten in: Nature communications | 2022

von Vo, J. | Wu, Y. | Mishler, J. | +37

80

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

enthalten in: Cancer cell | 2022

von Stuver, R. | Shah, G. | Korde, N. | +30